We are live on ! Find out more
CURX icon

Curanex Pharmaceuticals

11 hedge funds and large institutions have $140K invested in Curanex Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more capital inflows, than outflows

Capital inflows: $158K | Capital outflows: $94.7K

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

10% more funds holding

Funds holding: 10 → 11 (+1)

0.47% more ownership

Funds ownership: 1.03% → 1.5% (+0.47%)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Holders
11
Holders Change
+1
Holders Change %
+10%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
1
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

CURX Hedge Fund Activity: Q4 2025 in Review

11 of the 8,319 institutional investors tracked by Wall St. Rank reported a position in Curanex Pharmaceuticals (CURX) for Q4 2025, worth a combined $140K — down 32% from $206K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new CURX positions and 5 closed out — a net gain of 1 holder — while 1 added to existing stakes and 3 trimmed.

The largest buyer was DRW Securities, opening a new position worth an estimated $39.4K. The largest seller was UBS Group, cutting an estimated $28.3K.

  • 11 institutional investors held Curanex Pharmaceuticals (CURX) as of Q4 2025, up from 10 in Q3 2025.
  • Funds reported $140K of Curanex Pharmaceuticals stock for Q4 2025, down 32% quarter-over-quarter.
  • 6 funds opened new Curanex Pharmaceuticals positions in Q4 2025 and 5 closed out, a net change of +1 holder.
  • The largest Curanex Pharmaceuticals buyer in Q4 2025 was DRW Securities, an estimated $39.4K added.
  • The largest Curanex Pharmaceuticals seller in Q4 2025 was UBS Group, an estimated $28.3K sold.

Based on aggregated 13F filings for Q4 2025.